Home » Stocks » Alpine Immune Sciences

Alpine Immune Sciences, Inc. (ALPN)

Stock Price: $10.70 USD 0.06 (0.56%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 198.93M
Revenue (ttm) 2.83M
Net Income (ttm) -35.00M
Shares Out 23.73M
EPS (ttm) -1.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $10.70
Previous Close $10.64
Change ($) 0.06
Change (%) 0.56%
Day's Open 10.78
Day's Range 10.36 - 10.99
Day's Volume 40,174
52-Week Range 2.05 - 15.00

More Stats

Market Cap 198.93M
Enterprise Value 184.74M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 23.73M
Float 7.96M
EPS (basic) -1.89
EPS (diluted) -1.88
FCF / Share -1.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 45,190
Short Ratio n/a
Short % of Float 0.11%
Beta 1.88
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 70.27
PB Ratio 7.76
Revenue 2.83M
Operating Income -36.44M
Net Income -35.00M
Free Cash Flow -34.57M
Net Cash 14.19M
Net Cash / Share 0.76
Gross Margin -1,204.77%
Operating Margin -1,287.32%
Profit Margin -1,236.50%
FCF Margin -1,221.23%
ROA -38.95%
ROE -85.96%
ROIC -71.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$22.25*
(107.94% upside)
Low
19.0
Current: $10.70
High
27.0
Target: 22.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue1.740.711.732.950.49---
Revenue Growth146.81%-59.27%-41.32%499.59%----
Gross Profit1.740.711.732.950.49---
Operating Income-43.57-36.63-14.97-1.19-0.37-14.49-15.28-8.88
Net Income-41.85-36.49-7.78-1.23-0.37-14.66-16.20-9.57
Shares Outstanding18.3613.856.480.560.500.180.040.03
Earnings Per Share-2.28-2.63-1.20-2.18-0.74-81.08-418.00-278.80
Operating Cash Flow-35.35-28.42-16.57-3.804.82-14.45-14.29-9.52
Capital Expenditures-0.82-0.50-0.59-0.78-0.01--0.13-0.03
Free Cash Flow-36.17-28.91-17.16-4.584.81-14.45-14.42-9.55
Cash & Equivalents40.6552.3081.3711.8287.2527.813.600.00
Total Debt16.364.205.030.11--15.34-
Net Cash / Debt24.3048.1076.3411.7187.2527.81-11.750.00
Assets54.0954.8785.2212.6087.9128.544.13-
Liabilities24.6210.286.312.524.4244.3017.63-
Book Value29.4744.5978.92-1.4683.49-15.75-91.29-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Alpine Immune Sciences, Inc.
Country United States
Employees 53
CEO Mitchell H. Gold

Stock Information

Ticker Symbol ALPN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALPN

Description

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.